In a recent study, scientists found that for hospitalized patients with COVID-19, zinc sulfate may improve health outcomes.
The finding is from New York University. One researcher is Philip M. Carlucci.
Zinc sulfate is used as a dietary supplement to treat zinc deficiency and to prevent the condition in those at high risk.
In the study, the team collected data from electronic medical records for COVID-19 patients with admission.
They compared hospital outcomes for patients who received hydroxychloroquine and azithromycin plus zinc (411 patients) versus those who received hydroxychloroquine and azithromycin alone (521 patients).
The team found that zinc sulfate increased the frequency of patients being discharged home and reduced the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients not admitted to the ICU in univariate analyses.
The findings remained strong for increased frequency of being discharged home and reduction in mortality or transfer to hospice after adjustment for the time at which zinc sulfate was added to the protocol.
But the addition of zinc sulfate had no impact on the length of hospitalization, duration of ventilation or duration of intensive care unit (ICU) stay.
The team says these findings support the initiation of future randomized clinical trials testing zinc sulfate against COVID-19.
If you care about COVID-19, please read studies about single Pfizer COVID-19 vaccine 90% effective after 21 days and findings of vaccines against COVID-19 will have side effects – that’s a good thing.
For more information about COVID-19 and your health, please see recent studies about what heart and stroke patients should know about COVID-19 vaccines and results showing what happens after you get the COVID-19 vaccine?
Copyright © 2021 Knowridge Science Report. All rights reserved.
